Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Company profile
Ticker
INDV
Exchange
Website
CEO
Shaun Thaxter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
INDV stock data
Latest filings (excl ownership)
6-K
Transaction In Own Shares
30 Apr 24
6-K
Transaction In Own Shares
29 Apr 24
6-K
Transaction In Own Shares
26 Apr 24
6-K
Delivered Double-Digit Net Revenue Growth in Q1 2024; FY 2024 Guidance Reconfirmed
25 Apr 24
6-K
Transaction In Own Shares
25 Apr 24
6-K
Transaction In Own Shares
24 Apr 24
6-K
Transaction In Own Shares
23 Apr 24
6-K
Transaction In Own Shares
22 Apr 24
6-K
Transaction In Own Shares
19 Apr 24
6-K
Transaction In Own Shares
18 Apr 24
Latest ownership filings
SC 13G/A
SG Americas Securities, LLC
9 Apr 24
SC 13G
SG Americas Securities, LLC
9 Apr 24
SC 13D/A
Two Seas Capital LP
29 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
SC 13G
SCOPIA CAPITAL MANAGEMENT LP
14 Feb 24
SC 13G
MORGAN STANLEY
8 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
SC 13D
Two Seas Capital LP
2 Oct 23
Institutional ownership, Q3 2023
48.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 75 |
Opened positions | 20 |
Closed positions | 4 |
Increased positions | 18 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 1.76 tn |
Total shares | 65.74 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kairos Capital Management | 13.67 mm | $315.37 bn |
Scopia Capital Management | 8.31 mm | $191.74 bn |
Vanguard | 5.85 mm | $134.88 bn |
GS Goldman Sachs | 5.68 mm | $131.11 bn |
FMR | 5.50 mm | $119.34 bn |
Artemis Investment Management | 3.13 mm | $67.88 bn |
BAC Bank Of America | 2.70 mm | $62.33 bn |
Polar Capital | 2.62 mm | $60.47 bn |
Acadian Asset Management | 2.28 mm | $49.51 mm |
Liontrust Investment Partners | 2.00 mm | $43.34 bn |
News
Addiction Treatment Company, Indivior, Reports 12% YoY Growth For First Quarter Led By Sublocade Sales
25 Apr 24
Indivior Q1 2024 Adj EPS $0.37 Misses $0.41 Estimate, Sales $284.000M Miss $299.750M Estimate
25 Apr 24
Craig-Hallum Initiates Coverage On Indivior with Buy Rating, Announces Price Target of $37
3 Apr 24
This Nasal Spray Rapidly Reverses Effects Of Fentanyl Overdose And No, It's Not Naloxone
12 Mar 24
Indivior Announces Publication Demonstrating That OPVEE Nasal Spray Rapidly Reverses Effects Of Opioid-Induced Respiratory Depression In Head-To-Head Study Against Intranasal Naloxone
11 Mar 24
Press releases
Indivior Announces Q1 2024 Financial Results
25 Apr 24
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
11 Mar 24
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation
29 Feb 24
Indivior Announces Q4 / FY 2023 Financial Results
22 Feb 24